Squarepoint’s Astria Therapeutics ATXS Stock Holding History

Squarepoint’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,200	Closed	-$102K	–	4097
2024 Q2	$102K	Sell	11,200 -96,700	-90%	-$944K	﹤0.01%	3796
2024 Q1	$1.52M	Buy	+107,900	New	+$1.34M	﹤0.01%	2288

Squarepoint's ATXS Position: Q1 2026 in Review

Squarepoint sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 882,792 shares — an estimated $11.6M sold.

Squarepoint first reported a position in ATXS in Q4 2019 and held it in 7 quarters. The position peaked at $11.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Squarepoint reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 882,792 Astria Therapeutics shares in Q1 2026, an estimated $11.6M.
Squarepoint first reported a position in Astria Therapeutics in Q4 2019 and held it in 7 quarters.
Squarepoint's Astria Therapeutics position peaked at $11.6M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.